Clinical trials: Schizophrenia
Schizophrenia, Schizoaffective Disorder
A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents
Lurasidone (lurasidone HCl) is a novel psychotropic agent that is being developed as a potential new antipsychotic treatment for patients with schizophrenia.
- Trial name
- SWITCHCore (NCT01143077)
- Testing
- Lurasidone HCl
- Where
- 27 sites in United States
- Volunteers
- 244 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizo Affective Disorder, Schizophrenia
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients
- Conditions
- Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03751488
- Testing
- LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Study of RO4917838 in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (NN25307)
This randomized, multi-center, double-blind, parallel-group, placebo-controlled study will evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia.
- Trial name
- NCT01235520
- Testing
- RO4917838
- Where
- 121 sites in United States, Argentina and 12 more
- Volunteers
- 595 people
- Sponsor
- Hoffmann-La Roche
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
- Trial name
- NCT05654870
- Testing
- Valbenazine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences
Schizophrenia, Affective Symptoms
Atypical Antipsychotics in the Treatment of Affective Symptoms of Schizophrenia in Hungary
This is a noninterventional observational study lead amongst psychiatrists, to assess the the overall status of schizophrenic outpatients with affective symptoms treated with atypical antipsychotics.
- Trial name
- AFFECT (NCT01534936)
- Where
- 53 sites in Hungary
- Volunteers
- 2,153 people
- Sponsor
- AstraZeneca
Acute Schizophrenia
A Randomized, Active-controlled, Double-blind, Parallel-Goup Study of the Efficacy and Safety of Extended Release(ER) Paliperidone in the Treatment of Schizophrenia
This is a randomized (patients are assigned different treatments based on chance), double-blind (neither the patient nor the physician knows whether drug or placebo is being taken, or at what dosage), active-controlled…
- Trial name
- NCT00350467
- Testing
- ER OROS paliperidone and Olanzapine
- Where
- 7 sites in China
- Volunteers
- 288 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Schizophrenia
An Open Label Multicentre Study to Determine the Dose Distribution of Paliperidone ER in Patients With Schizophrenia
The purpose of this trial is to evaluate the dose distribution, effectiveness and safety in patients with schizophrenia who are switched from an oral atypical antipsychotic to Paliperidone ER.
- Trial name
- NCT00473434
- Testing
- Paliperidone
- Volunteers
- 64 people
- Sponsor
- Janssen-Cilag Pty Ltd
Bipolar Disorder, Mood Disorders
A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder
The purpose of this study is to evaluate the effectiveness and safety of 3 different doses of paliperidone extended release (ER) compared to placebo in patients diagnosed with Bipolar I Disorder who are experiencing an acute…
- Trial name
- NCT00299715
- Testing
- Paliperidone extended-release
- Volunteers
- 473 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
- Trial name
- NCT01412060
- Testing
- Cariprazine
- Where
- 73 sites in United States, India and 3 more
- Volunteers
- 765 people
- Sponsor
- Forest Laboratories
Schizophrenia
Study to Evaluate the Safety and Efficacy of Ublituximab in Participants With Schizophrenia
The main objective of this Phase 2 study is to assess the efficacy of ublituximab as measured by Positive and Negative Syndrome Scale (PANSS) total score in participants with schizophrenia.
- Trial name
- NCT07680946
- Testing
- Ublituximab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- TG Therapeutics, Inc.
Schizophrenia
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
This study will evaluate the safety and durability of effect of ALKS 9072 (also known as ALKS 9070) during long-term treatment of subjects with stable schizophrenia.
- Trial name
- NCT01626456
- Testing
- ALKS 9072, Low, ALKS 9072, High
- Where
- 82 sites in United States, Bulgaria and 6 more
- Volunteers
- 478 people
- Sponsor
- Alkermes, Inc.
Schizophrenia
Safety and Tolerability of Single and Multiple Doses of LB-102 in Healthy Adults
A Single Ascending Dose (SAD; Part A) and Multiple Ascending Dose (MAD; Part B) Phase 1 Study of LB-102 N-Methyl amisulpride) in healthy volunteers.
- Trial name
- NCT04187560
- Testing
- LB-102
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- LB Pharmaceuticals Inc.
Schizophrenia
Seroquel XR in Adults With Schizophrenia
The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally…
- Trial name
- NCT00852631
- Testing
- Quetiapine fumarate (Seroquel)
- Where
- 3 sites in Thailand
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis
A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017
This is a phase 1，randomized, double-blind, placebo-controlled, SAD study to evaluate the safety, tolerability and pharmacokinetics of oral LPM526000133 Fumarate Capsules (LY03017) in healthy adult subjects.
- Conditions
- Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis, Hallucinations and Delusions Associated With Parkinson Disease Psychosis, Negative Symptoms of Schizophrenia
- Trial name
- NCT06388551
- Testing
- LY03017
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia
A Comparison of Seroquel vs. Risperidone in Schizophrenia
The purpose of this study is to show equal efficacy of both quetiapine and risperidone in subjects treated with study medication for up to 8 weeks.
- Trial name
- NCT00034905
- Testing
- quetiapine fumarate vs risperidone
- Where
- 64 sites in United States
- Sponsor
- AstraZeneca
Schizophrenia
Safety and Tolerability of Multiple Doses of ITI-214 in Healthy Adults and in Adults With Stable Schizophrenia
The purpose of this study is to characterize the safety and tolerability profile of ITI-214 when administered as multiple doses of oral solution at escalating dose levels.
- Trial name
- NCT01900522
- Testing
- ITI-214 Dose A, ITI-214 Dose B, ITI-214 Dose C
- Where
- 2 sites in United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Takeda
Schizophrenia
A Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Male and Female Subjects With Schizophrenia
This is a single-center, randomized, single-blind, placebo-controlled, ascending single oral dose study designed to evaluate the safety, tolerability, and pharmacokinetic (PK) profiles of SEP-363856 and its metabolite SEP-363854…
- Trial name
- NCT01940159
- Testing
- SEP-363856
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in…
- Trial name
- NCT05227703
- Testing
- Emraclidine 15 mg, Emraclidine 30 mg
- Where
- 26 sites in United States, Bulgaria and 1 more
- Volunteers
- 391 people
- Sponsor
- AbbVie
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.